

PUBBLICAZIONI SCIENTIFICHE 2019 DEL CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI, FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO

	TITOLO PAPER	AUTORI	RIVISTA	ANNO	VOLUME	ISSUE	PAGINE	DOI	TIPO DI PUBBLICAZIONE
1	Further comments on: High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis	Messori A, Peyvandi F , Trippoli S, Palla R , Rosendaal FR, Mannucci PM .	Blood Transfusion	2019	17	-	86	10.2450/2017.0253-17	Lettera opinion
2	Antithrombin During Extracorporeal Membrane Oxygenation in Adults: National Survey and Retrospective Analysis.	Iapichino GE, Protti A, Andreis DT, Panigada M, Artoni A , Novembrino C , Pesenti A, Gattinoni L	ASAIO Journal	2019	65	3	257	10.1097/MAT.0000000000000806	Articolo originale
3	Direct oral anticoagulants and cirrhosis: More evidence still needed for efficacy and safety in portal vein thrombosis.	Mannucci PM , Tripodi A .	Vascular Pharmacology	2019	113	-	01-apr	10.1016/j.vph.2018.06.005	Review
4	Evaluation of the Utility of von Willebrand Factor Propeptide in the Differential Diagnosis of von Willebrand Disease and Acquired von Willebrand Syndrome.	Stufano F , Boscarino M , Bucciarelli P , Baronciani L , Maino A , Cozzi G , Peyvandi F .	Seminars in Thrombosis and Hemostasis	2019	45	1	36	10.1055/s-00381660481	Articolo originale
5	Preemptive-TIPS improves outcome in high-risk variceal bleeding: An observational study.	Hernández-Gea V, Procopet B, Giráldez Á, Amitrano L, Villanueva C, Thabut D, Ibañez-Samaniego L, Silva-Junior G, Martínez J, Genescà J, Bureau C, Trebicka J, Llop E, Laleman W, Palazon JM, Castellote J, Rodrigues S, Gluud LL, Noronha Ferreira C, Barcelo R, Cañete N, Rodríguez M, Ferlitsch A, Mundi JL, Gronbaek H, Hernández-Guerra M, Sassatelli R, Dell'Era A, Senzolo M, Abraldes JG, Romero-Gómez M, Zipprich A, Casas M, Masnou H, Primignani M, Krag A, Nevens F, Calleja JL, Jansen C, Robic MA, Conejo I, Catalina MV, Albillos A, Rudler M, Alvarado E, Guardascione MA, Tantau M, Bosch J, Torres F, García-Pagán JC; International Variceal Bleeding Observational Study Group and Baveno Cooperation (La Mura V) .	Hepatology	2019	69	1	282	10.1002/hep.30182	Multicentrico NO Profit
6	Angioedema and emergency medicine: From pathophysiology to diagnosis and treatment.	Depetri F, Tedeschi A, Cugno M .	European Journal of Internal Medicine	2019	59	-	8	10.1016/j.ejim.2018.09.004	Review
7	Author reply.	La Mura V , Primignani M.	Clinical Gastroenterology and Hepatology	2019	17	4	798	10.1016/j.cgh.2018.09.011	Lettera opinion
8	Renin-angiotensin-aldosterone system in cirrhosis: There's room to try!	Di Pascoli M, La Mura V	Digestive and Liver Disease	2019	51	2	297	10.1016/j.dld.2018.07.038	Editoriale
9	Advances in the Treatment of Hemophilia: Implications for Laboratory Testing.	Tripodi A , Chantarangkul V , Novembrino C , Peyvandi F .	Clinical Chemistry	2019	65	2	254	10.1373/clinchem.2017.284356	Review
10	Phase 3 Study of Recombinant von Willebrand Factor in Patients With Severe von Willebrand Disease Who Are Undergoing Elective Surgery.	Peyvandi F , Mamaev A, Wang JD, Stasyshyn O, Timofeeva M, Curry N, Cid AR, Yee TT, Kavakli K, Castaman G, Sytkowski A.	Journal of Thrombosis and Haemostasis	2019	17	1	52	10.1111/jth.14313	Articolo originale
11	Severe acquired von Willebrand syndrome secondary to systemic lupus erythematosus.	Stufano F , Baronciani L , Biguzzi E , Cozzi G , Colpani P , Chisini M , Peyvandi F	Haemophilia	2019	25	1	e30	10.1111/hae.13626	Lettera con dati
12	Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication, and strategies for difficult-to-treat patients.	Ljung R, Auerswald G, Benson G, Dolan G, Duffy A, Hermans C, Jiménez-Yuste V, Lambert T, Morfini M, Zupančić-Šalek S, Santagostino E .	European Journal of Haematology	2019	102	2	111	10.1111/ejh.13193	Review
13	The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.	Oldenburg J, Mahlangu JN, Bujan W, Trask P, Callaghan MU, Young G, Asikanius E, Peyvandi F , Santagostino E , Kruse-Jarres R, Negrier C, Kessler C, Xu J, Windyga J, Shima M, von Mackensen S.	Haemophilia	2019	25	1	33	10.1111/hae.13618	Articolo originale
14	Requirement of a reference measurement system for the tissue factor-induced coagulation time and the international normalized ratio.	van den Besselaar AMHP, van Rijn CJJ, Hubbard AR, Kitchen S, Tripodi A , Cobbaert CM.	Clinical Chemistry and Laboratory Medicine	2019	57	7	e169	10.1515/cclm-2018-1194	Lettera con dati
15	Treatment of rare factor deficiencies other than hemophilia.	Menegatti M , Peyvandi F .	Blood	2019	133	5	415	10.1182/blood-2018-06-820738	Review
16	Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients.	Schelpe AS, Roose E, Joly BS, Pareyn I, Mancini I, Biganzoli M , Deckmyn H, Voorberg J, Fijnheer R, Peyvandi F , De Meyer SF, Coppo P, Veyradier A, Vanhoorelbeke K.	Haematologica	2019	104	6	1268	10.3324/haematol.2018.205666	Articolo originale

17	Haploidentical Hematopoietic Stem Cell Transplant complicated by Atypical Hemolytic Uremic Syndrome and Kidney Transplant from the same donor with no Immunosuppression but C5 Inhibition	Ardissino G, Cresseri D, Giglio F, Onida F, Iannuzzella F, Tel F, Giussani A, Messa P, Longhi S, Vincenti D, Tedeschi S, Cugno M , Ciceri F.	Transplantation	2019	103	2	e48	10.1097/TP.00000000002505	Case Report
18	Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.	Scully M, Cataland SR, Peyvandi F , Coppo P, Knöbl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK; HERCULES Investigators	New England Journal of Medicine	2019	380	4	335	10.1056/NEJMOA180631	Multicentrico Profit
19	Prevention of relapse in patients with acquired thrombotic thrombocytopenic purpura undergoing elective surgery: a case series.	Arcudi S, Ferrari B , Pontiggia S , Tufano A, Artoni A , Mancini I , Peyvandi F	Journal of Thrombosis and Haemostasis	2019	17	3	492	10.1111/jth.14381	Articolo originale
20	Sex-Differences in the Pattern of Comorbidities, Functional Independence, and Mortality in Elderly Inpatients: Evidence from the RePoSI Register.	Corrao S, Argano C, Natoli G, Nobili A, Corazza GR, Mannucci PM , Perticone F; REPOSI Investigators (Peyvandi F, Ferrari B, Rossio R)	Journal of Clinical Medicine	2019	8	1	81	10.3390/jcm8010081	Multicentrico NO Profit
21	Thrombin generation assay for testing hemostatic effect of factor VIII concentrates in patients with hemophilia A and inhibitors: In vitro results from the PredicTGA study.	Tripodi A , Chantarangkul V , Clerici M , Bader R , Anzoletti MB , Peyvandi F , Santagostino EM ; PredicTGA Collaborators.	Thrombosis Research	2019	174	-	84	10.1016/j.thromres.2018.12.007	Lettera con dati
22	Body mass index reduction improves the baseline procoagulant imbalance of obese subjects.	Tripodi A , Primignani M, Badiali S, de Ruberto F, Granelli P, Tosetti G, Clerici M , Padovan L , Chantarangkul V , Scalabrino E , Peyvandi F.	Journal of Thrombosis and Thrombolysis	2019	48	1	52	10.1007/s11239-019-01818-9	Articolo originale
23	Role of the factor VIII-binding capacity of endogenous von Willebrand factor on the development of factor VIII inhibitors in patients with severe hemophilia A.	Repešš Y, Costa C, Palla R , Farrokhi Moshai E, Borel-Derlon A, D'Oiron R, Rothschild C, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Oldenburg J, Pavlova A, Rosendaal FR, Peyvandi F , Kaveri SV, Lacroix-Desmazes S	Haematologica	2019	104	8	e369	10.3324/haematol.2018.212001	Lettera con dati
24	Establishment of the WHO 2nd International Standard Factor V, plasma (16/374): Communication from the SSC of the ISTH.	Hubbard AR, Thelwell C, Rigby P; subcommittee on factor viii factor ix, rare coagulation disorders (Peyvandi F)	Journal of Thrombosis and Haemostasis	2019	17	4	695	10.1111/jth.14403	Multicentrico Collaborators
25	A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.	Peyvandi F , Castaman G, Greslele P, De Cristofaro R, Schinco P, Bertomoro A, Morfini M, Gamba G, Barillari G, Jiménez-Yuste V, Königs C, Iorio A, Federici AB	Blood Transfusion	2019	17	-	391	10.2450/2019.0183-18.	Articolo originale
26	Risk of diagnostic delay in congenital thrombotic thrombocytopenic purpura.	Ferrari B , Cairo A , Pagliari MT , Mancini I , Arcudi S , Peyvandi F	Journal of Thrombosis and Haemostasis	2019	17	4	666	10.1111/jth.14409	Case Report
27	Understanding the Impact of Aberrant Splicing in Coagulation Factor V Deficiency.	Paraboschi EM, Menegatti M , Peyvandi F , Duga S, Asselta R	International Journal of Molecular Sciences	2019	20	4	910	10.3390/ijms20040910	Articolo originale
28	Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting.	Kruse-Jarres R, Oldenburg J, Santagostino E , Shima M, Kempton CL, Kessler CM, Lehle M, Chebon S, Selak Bienz N, Asikanius E, Mahlangu J.	Haemophilia	2019	25	2	213	10.1111/hae.13655	Articolo originale
29	Position paper on laboratory testing for patients with haemophilia. A consensus document from SISET, AICE, SIBioC and SIPMeL.	Tripodi A , Santoro RC, Testa S, Molinari AC, Bernardini S, Golato M, Lippi G, Ageno W, Santagostino E.	Blood Transfusion	2019	17	3	229	10.2450/2019.0241-18	Articolo originale
30	Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A.	Di Minno G, Santagostino E , Morfini M, Ettorre C, Cultrera D, Baldacci E, Russo E, Gallucci C	Patient Preference and Adherence	2019	13	-	233	10.2147/PPA.S175254	Multicentrico NO Profit
31	Inhibitors: A Need for Eradication?	Santagostino E , Young G, Escuriola Ettingshausen C, Jimenez-Yuste V, Carcao M.	Acta Haematologica	2019	141	3	151	10.1159/000495454	Review
32	Rapid and sustained immune tolerance to inhibitors induced by a plasma-derived, VWF-containing FVIII concentrate.	Santagostino E , Rangarajan S, Oldenburg J, Peiró-Jordan R, Jiménez-Yuste V.	Haemophilia	2019	25	2	e110	10.1111/hae.13676	Lettera con dati
33	Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis.	Intagliata NM, Caldwell SH, Tripodi A.	Gastroenterology	2019	156	6	1582	10.1053/j.gastro.2019.01.265	Review
34	Telemedicine and telerehabilitation: current and forthcoming applications in haemophilia.	Boccalandro EA , Dallari G, Mannucci PM.	Blood Transfusion	2019	17	-	385	10.2450/2019.0218-18	Review
35	Evaluation of three "beyond Baveno VI" criteria to safely spare endoscopies in compensated advanced chronic liver disease.	Tosetti G, Primignani M, La Mura V , D'Ambrosio R, Degaspero E, Mezzina N, Viganò M, Rumi M, Fracanzani AL, Lombardi R, Fargion S, Fraquelli M, Aghemo A, Lampertico P.	Digestive and Liver Disease	2019	51	8	1135	10.1016/j.dld.2018.12.025	Articolo originale

36	Complications of whole-exome sequencing for causal gene discovery in primary platelet secretion defects.	Gorski MM, Lecchi A, Femia EA, La Marca S, Cairo A, Pappalardo E, Lotta LA, Artoni A, Peyvandi F.	Haematologica	2019	104	10	2084	10.3324/haematol.2018.204990	Articolo originale
37	Hypercoagulability and the risk of recurrence in young women with myocardial infarction or ischaemic stroke: a cohort study.	Maino A, Algra A, Peyvandi F , Rosendaal FR, Siegerink B.	BMC Cardiovascular Disorders	2019	19	1	55	10.1186/s12872-019-1040-4.	Articolo originale
38	Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids.	Proietti M, Agosti P, Lonati C, Corrao S, Perticone F, Mannucci PM , Nobili A, Harari S; REPOSI Investigators (Peyvandi F, Rossio R, Ferrari B)	Journal of the American Medical Directors Association	2019	20	10	1313	10.1016/j.jamda.2019.01.132.	Multicentrico NO Profit
39	Clinical and Laboratory Features of Patients with Acquired Thrombotic Thrombocytopenic Purpura: Fourteen Years of the Milan TTP Registry.	Mancini I, Pontiggia S, Palla R, Artoni A, Valsecchi C, Ferrari B , Mikovic D, Peyvandi F ; Italian Group of TTP Investigators.	Thrombosis and Haemostasis	2019	119	5	695	10.1055/s-0039-1679907	Multicentrico NO Profit
40	Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).	Curry N, Albayrak C, Escobar M, Andre Holme P, Kearney S, Klamroth R, Misgav M, Négrier C, Wheeler A, Santagostino E , Shima M, Landorph A, Tønder SM, Lentz SR.	Haemophilia	2019	25	3	373	10.1111/hae.13712.	Multicentrico Profit
41	Total IgE and atopic status in patients with severe chronic spontaneous urticaria unresponsive to omalizumab treatment.	Asero R, Ferrucci S, Casazza G, Marzano AV, Cugno M.	Allergy	2019	74	8	1561	10.1111/all.13754	Lettera con dati
42	Need for De-Prescribing in Hospital Elderly Patients Discharged with Limited Life Expectancy: The REPOSI Study.	Pasina L, Brignolo Ottolini B, Cortesi L, Tettamanti M, Franchi C, Marengoni A, Mannucci PM , Nobili A and the REPOSI Investigators (Peyvandi F, Rossio R, Ferrari B)	MEDICAL PRINCIPLES AND PRACTICE	2019	28	-	501	10.1159/000499692	Multicentrico NO Profit
43	Metabolomics discloses potential biomarkers to predict the acute HVPg response to propranolol in patients with cirrhosis.	Reverter E, Lozano JJ, Alonso C, Berzigotti A, Seijo S, Turon F, Baiges A, Martínez-Chantar ML, Mato JM, Martínez-Arranz I, La Mura V , Hernández-Gea V, Bosch J, García-Pagán JC	Liver International	2019	39	4	705	10.1111/liv.14042	Articolo originale
44	Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement.	Santagostino E, Mancuso ME, Novembrino C , Solimeno LP, Tripodi A, Peyvandi F.	Haematologica	2019	104	8	e380	10.3324/haematol.2018.215129	Case Report
45	Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis.	Samuelson Bannow B, Recht M, Négrier C, Hermans C, Berntorp E, Eichler H, Mancuso ME , Klamroth R, O'Hara J, Santagostino E , Matsushita T, Kessler C.	Blood Reviews	2019	35	-	43	10.1016/j.blre.2019.03.002	Review
46	An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays.	Cini M, Legnani C, Testa S, Tripodi A , Cosmi B, Palareti G.	International Journal of Laboratory Hematology	2019	41	3	309	10.1111/ijlh.12974	Articolo originale
47	Main Oral Manifestations in Immune-Mediated and Inflammatory Rheumatic Diseases.	Gualtierotti R, Marzano AV, Spadari F, Cugno M.	Journal of Clinical Medicine	2019	8	1	22	10.3390/jcm8010021	Review
48	Consensus statements on vaccination in patients with haemophilia-Results from the Italian haemophilia and vaccinations (HEVA) project.	Santagostino E , Riva A, Cesaro S, Esposito S, Marino D, Mazzucchelli RI, Molinari AC, Mura R, Notarangelo LD, Tagliaferri A, Di Minno G, Clerici M; the HEVA Study Group (Peyvandi F).	Haemophilia	2019	25	4	656	10.1111/hae.13756	Multicentrico NO Profit
49	Paradoxical Skin Reactions to Biologics in Patients With Rheumatologic Disorders.	Garcovich S, De Simone C, Genovese G, Berti E, Cugno M , Marzano AV.	Frontiers in Pharmacology	2019	10	-	282	10.3389/fphar.2019.00282	Review
50	The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab.	Carcao M, Escuriola-Ettingshausen C, Santagostino E , Oldenburg J, Liesner R, Nolan B, Bátorová A, Haya S, Young G; Future of Immunotolerance Treatment Group	Haemophilia	2019	25	4	676	10.1111/hae.13762.	Multicentrico NO Profit
51	Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS).	Mahlangu J, Oldenburg J, Callaghan MU, Shima M, Mancuso ME , Trask P, Recht M, Garcia C, Yang R, Lehle M, Macharia H, Asikanius E, Levy GG, Kruse-Jarres R, von Mackensen S.	Haemophilia	2019	25	3	382	10.1111/hae.13731	Multicentrico Profit
52	Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants	Testa S, Legnani C, Antonucci E, Paoletti O, Dellanoce C, Cosmi B, Pengo V, Poli D, Morandini R, Testa R, Tripodi A , Palareti G; Coordinator of START2-Register	Journal of Thrombosis and Haemostasis	2019	17	7	1064	10.1111/jth.14457	Multicentrico NO Profit
53	Evaluation of an automated chromogenic assay for Factor VIII clotting activity measurement in patients affected by haemophilia A.	Novembrino C, Boscolo Anzoletti M, Mancuso ME , Shinohara S, Peyvandi F	Haemophilia	2019	25	3	521	10.1111/hae.13746	Articolo originale
54	Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies.	Volkers P, Hanschmann KM, Calvez T, Chambost H, Collins PW, Demiguel V, Hart DP, Hay CRM, Goudemand J, Ljung R, Palmer BP, Santagostino E , van Hardeveld EM, van den Berg M, Keller-Stanislawski B.	Haemophilia	2019	25	3	398	10.1111/hae.13747.	Articolo originale
55	Antibiotic use and associated factors in a large sample of hospitalized older people.	Ardoino I, Mannucci PM , Nobili A, Franchi C; REPOSI collaborators (Peyvandi F, Ferrari B, Rossio R).	Journal of Global Antimicrobial Resistance	2019	19	December 2019	167	10.1016/j.jgar.2019.04.013	Multicentrico NO Profit

56	Simulation-based education for physicians to increase oral anticoagulants in hospitalized elderly patients with atrial fibrillation.	Franchi C, Antoniazzi S, Ardoino I, Proietti M, Marcucci M, Santalucia P, Monzani V, Mannucci PM , Nobili A; SIM-AF Collaborators (Peyvandi F, Rossio R) .	American Journal of Medicine	2019	132	8	e634	10.1016/j.amjmed.2019.03.052	Multicentrico NO Profit
57	Common themes and challenges in hemophilia care: a multinational perspective	Stoffman J, Andersson NG, Branchford B, Batt K, D'Oiron R, Escuriola E, Etinghausen C, Hart DP, Jiménez Yuste V, Kavakli K, Mancuso ME , Nogami K, Ramirez C, Wu R	Hematology	2019	24	1	39	10.1080/10245332.2018.1505225	Articolo originale
58	Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIII-Fc) compared with conventional products in haemophilia A: the A-SURE study.	Oldenburg J, Hay CRM, Jiménez-Yuste V, Peyvandi F , Schved JF, Szamosi J, Winding B, Lethagen S.	BMJ Open	2019	30	5	e028012	10.1136/bmjopen-2018-028012	Articolo originale
59	Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP.	Davis J, Yan S, Matsushita T, Alberio L, Bassett P, Santagostino E .	Journal of Medical Economics	2019	22	10	1014	10.1080/13696998.2019.1620246	Articolo originale
60	Emicizumab for hemophilia A without inhibitors.	Cafur L, Kruse-Jarres R, Mancuso ME , Kempton CL	Expert Review of Hematology	2019	12	7	515	10.1080/17474086.2019.1624519	Review
61	Mechanisms of Inflammation in Neutrophil-Mediated Skin Diseases.	Marzano AV, Ortega-Loayza AG, Heath M, Morse D, Genovese G, Cugno M .	Frontiers in Immunology	2019	10	-	1059	10.3389/fimmu.2019.01059	Review
62	Baseline D-dimer plasma levels correlate with disease activity but not with the response to omalizumab in chronic spontaneous urticaria.	Asero R, Marzano AV, Ferrucci S, Genovese G, Cugno M .	Allergy	2019	74	12	2538	10.1111/all.13936	Lettera con dati
63	Drug-drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients.	Gallo P, De Vincentis A, Pedone C, Nobili A, Tettamanti M, Gentilucci UV, Picardi A, Mannucci PM , Incalzi RA; REPOSI Investigators (Peyvandi F, Rossio R, Ferrari B) .	European Journal of Internal Medicine	2019	65	-	51	10.1016/j.ejim.2019.05.002	Multicentrico NO Profit
64	Analysis of factor V in zebrafish demonstrates minimal levels needed for early hemostasis.	Weyand AC, Grzegorski SJ, Rost MS, Lavik KI, Ferguson AC, Menegatti M , Richter CE, Asselta R, Duga S, Peyvandi F , Shavit JA.	Blood Advances	2019	3	11	1670	10.1182/bloodadvances.2018029066	Articolo originale
65	Timing of inhibitor development in >1000 previously untreated patients with severe hemophilia A.	van den Berg HM, Fischer K, Carcao M, Chambost H, Kenet G, Kurnik K, Königs C, Male C, Santagostino E , Ljung R.	Blood	2019	134	3	317	10.1182/blood.2019000658	Lettera con dati
66	Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects	De Cristofaro R, Sacco M, Lancellotti S, Berruti F, Garagiola I, Valsecchi C , Basso M, Di Stasio E, Peyvandi F	TH open	2019	3	2	e123	10.1055/s-0039-1688413.	Articolo originale
67	Appropriateness of prescription of oral anticoagulant therapy in acutely hospitalized older people with atrial fibrillation. Secondary analysis of the SIM-AF cluster randomized clinical trial.	Antoniazzi S, Ardoino I, Proietti M, Monzani V, Mannucci PM , Nobili A, Franchi C; SIM-AF Collaborators. (Peyvandi F, Rossio R)	British Journal of Clinical Pharmacology	2019	85	9	2134	10.1111/bcp.14029	Multicentrico NO Profit
68	Inappropriate prescription of benzodiazepines in acutely hospitalized older patients.	Franchi C, Rossio R , Ardoino I, Mannucci PM , Nobili A; REPOSI collaborators (Peyvandi F, Ferrari B) .	European Neuropsychopharmacology	2019	29	7	871	10.1016/j.euroneuro.2019.05.004	Multicentrico NO Profit
69	Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor.	Peyvandi F , Kouides P, Turecek PL, Dow E, Berntorp E.	Blood Reviews	2019	38	-	100572	10.1016/j.blre.2019.04.001	Review
70	Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.	Shah A, Solms A, Wiegmann S, Ahsman M, Berntorp E, Tiede A, Iorio A, Mancuso ME , Zhivkov T, Lissitchkov T.	Annals of Hematology	2019	98	9	2035	10.1007/s00277-019-03747-2	Articolo originale
71	Acquired platelet dysfunction and overproduction of platelet cyclic AMP in two patients with myeloid malignancies.	Lecchi A, Femia EA, La Marca S, Onida F, Artoni A .	Platelets	2019	30	8	1053	10.1080/09537104.2019.1636020	Case Report
72	Clinical advances in gene therapy updates on clinical trials of gene therapy in haemophilia	Peyvandi F, Garagiola I .	Haemophilia	2019	25	5	738	10.1111/hae.13816	Review
73	Burden of mild haemophilia A: Systematic literature review.	Peyvandi F , Tavakkoli F, Frame D, Quinn J, Kim B, Lawal A, Lee MC, Wong WY	Haemophilia	2019	25	5	755	10.1111/hae.13777	Articolo originale
74	D-dimer levels during and after anticoagulation withdrawal in patients with venous thromboembolism treated with non-vitamin K anticoagulants.	Legnani C, Martinelli I , Palareti G, Ciavarella A , Poli D, Ageno W, Testa S, Mastroiacovo D, Ciammaichella M, Bucherini E, Mumoli N, Cosmi B.	PloS One	2019	14	7	e0219751	10.1371/journal.pone.0219751	Articolo originale
75	Coagulation and Skin Autoimmunity.	Cugno M , Borghi A, Garcovich S, Marzano AV.	Frontiers in Immunology	2019	10	-	1407	10.3389/fimmu.2019.01407	Review

76	New Insights Into the Pathogenesis of Bullous Pemphigoid: 2019 Update.	Genovese G, Di Zenzo G, Cozzani E, Berti E, Cugno M , Marzano AV.	Frontiers in Immunology	2019	10	-	1506	10.3389/fimmu.2019.01506	Review
77	Switching patients in the age of long-acting recombinant products?	Escobar M, Santagostino E , Mancuso ME , Coppens M, Balasa V, Taylor JA, Iorio A, Negrier C.	Expert Review of Hematology	2019	12	Suppl 1	1	10.1080/17474086.2018.1564032.	Review
78	Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A.	Chowdary P, Carcao M, Holme PA, Jiménez-Yuste V, Lentz SR, Møss J, Poulsen LH, Shen C, Tosetto A, Wheeler A, Santagostino E .	Research and Practice in Thrombosis and Haemostasis	2019	3	3	542	10.1002/rth.212220	Articolo originale
79	Phase 3 Study of Recombinant von Willebrand Factor in Patients With Severe von Willebrand Disease Who Are Undergoing Elective Surgery: Reply	Peyvandi F	Journal of Thrombosis and Haemostasis	2019	17	8	1405	10.1111/jth.14545	Lettera opinion
80	International Society on Thrombosis and Haemostasis core curriculum project: core competencies in laboratory thrombosis and hemostasis.	Moffat KA, Kiencke V, Blanco AN, McLintock C, Peyvandi F , de Maat MPM, Adams MJ, Angchaisuksiri P, Nair S, Tsuda H, Haddad M, Renné T, Clark RC, Ross MT.	Journal of Thrombosis and Haemostasis	2019	17	11	1848	10.1111/jth.14601	Articolo originale
81	Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients.	Carlotta Franchi, Raffaella Rosso , Ilaria Ardoino, Alessandro Nobili, Pier Mannuccio Mannucci ; REPOSI collaborators (Peyvandi F, Ferrari B) .	European Journal of Internal Medicine	2019	68	-	e7	10.1016/j.ejim.2019.07.025	Multicentrico NO Profit
82	Real-life experience in switching to new extended half-life products at European haemophilia centres.	Peyvandi F , Garagiola I , Boscarino M , Ryan A, Hermans C, Makris M.	Haemophilia	2019	25	6	946	10.1111/hae.13834	Articolo originale
83	Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis.	Sigon G, D'Ambrosio R, Clerici M , Pisano G, Chantarangkul V , Sollazzi R, Lombardi R, Peyvandi F , Lampertico P, Fargion S, Tripodi A , Fracanzani AL	Liver International	2019	39	12	2309	10.1111/liv.14213	Articolo originale
84	Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper.	Barbui T, De Stefano V, Falanga A, Finazzi G, Martinelli I , Rodeghiero F, Vannucchi AM, Barosi G	Blood Cancer Journal	2019	9	8	61	10.1038/s41408-019-0225-5.	Articolo originale
85	Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.	Monagle P, Lensing AWA, Thelen K, Martinelli I , Male C, Santamaria A, Samochatova E, Kumar R, Holzhauser S, Saracco P, Simioni P, Robertson J, Grangl G, Halton J, Connor P, Young G, Molinari AC, Nowak-Göttl U, Kenet G, Kapsa S, Willmann S, Pap AF, Becka M, Twomey T, Beyer-Westendorf J, Prins MH, Kubitzka D; EINSTEIN-Jr Phase 2 Investigators (Abbattista M, Artoni A) .	Lancet Haematology	2019	6	10	e500	10.1016/S2352-3026(19)30161-9	Multicentrico Profit
86	Patterns of infections in older patients acutely admitted to medical wards: data from the REPOSI register.	Rossio R , Ardoino I, Franchi C, Nobili A, Mannuccio Mannucci P , Peyvandi F ; REPOSI Investigators (Ferrari B) .	Internal and Emergency Medicine	2019	14	8	1347	10.1007/s11739-019-02178-1	Multicentrico NO Profit
87	Pharmacokinetics of a new human plasma-derived double virus inactivated and nanofiltered factor IX concentrate in previously treated severe or moderately severe haemophilia B patients.	Castaman G, Borchellini A, Santagostino E , Tagariello G, Serban M, Uscatescu M, Truica C, Albert F, Morfini M.	Haemophilia	2019	25	6	e364	10.1111/hae.13828	Lettera con dati
88	Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial.	Santagostino E , Lalezari S, Reding MT, Ducore J, Ng HJ, Poulsen LH, Michaels LA, Linardi CCG	Thrombosis Research	2019	183	-	13	10.1016/j.thromres.2019.08.023	Multicentrico Profit
89	Pregnancy after cerebral venous thrombosis.	Abbattista M , Capecchi M, Martinelli I	Thrombosis Research	2019	181	Suppl 1	S15	10.1016/S0049-3848(19)30360-3.	Articolo originale
90	Reversal agents for oral anticoagulant-associated major or life-threatening bleeding.	Moia M , Squizzato A.	Internal and Emergency Medicine	2019	14	8	1233	10.1007/s11739-019-02177-2	Review
91	A human antithrombin isoform dampens inflammatory responses and protects from organ damage during bacterial infection.	Papareddy P, Rossnagel M, Doreen Hollwedel F, Kilic G, Veerla S, Naudin C, Smeds E, Westman J, Martinez-Martinez I, Egesten A, de la Morena-Barrio ME, Corral J, Linder A, Artoni A , Abbattista M , Novembrino C , Herbert Brakebusch C, Martinelli I , Kasetty G, Herwald H.	Nature Microbiology	2019	4	12	2442	10.1038/s41564-019-0559-6	Articolo originale
92	Aging with Hemophilia: The Challenge of Appropriate Drug Prescription.	Mannucci PM	Mediterranean Journal of Hematology and Infectious Diseases	2019	11	1	e2019056	10.4084/MJHID.2019.056	Review

93	Evaluation of a New, Rapid, Fully Automated Assay for the Measurement of ADAMTS13 Activity.	Valsecchi C , Mirabet M, Mancini I, Biganzoli M , Schiavone L , Faraudo S, Mane-Padros D, Giles D, Serra-Domenech J, Blanch S, Trisolini SM, Facchini L, Rinaldi E, Peyvandi F .	Thrombosis and Haemostasis	2019	119	11	1767	10.1055/s-0039-1696718	Articolo originale
94	Immune tolerance induction with moroctocog-alpha (Refacto/Refacto AF) in a population of Italian haemophilia A patients with high-titre inhibitors: Data from REF.IT Registry.	Zanon E, Pasca S, Pollio B, Santagostino E , Linari S, Tagliaferri A, Santoro C, Rocino A, Marino R, Aru B, Borchiellini A, Siragusa S, Coppola A.	Haemophilia	2019	25	6	1003	10.1111/hae.13859	Articolo originale
95	Editorial: Neutrophil-Mediated Skin Diseases: Immunology and Genetics.	Marzano AV, Lipsker D, Cugno M .	Frontiers in Immunology	2019	10	-	2377	10.3389/fimmu.2019.02377	Editoriale
96	Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis.	Gualtierotti R, Ingegnoli F, Boscolo M , Griffini S , Grovetti E , Cugno M .	Advances in Therapy	2019	36	12	3494	10.1007/s12325-019-01118-x	Articolo originale
97	Antithrombin supplementation during extracorporeal membrane oxygenation: study protocol for a pilot randomized clinical trial.	Panigada M, Spinelli E, Cucino A, Cipriani E, De Falco S, Panarello G, Occhipinti G, Arcadipane A, Sales G, Fanelli V, Brazzi L, Novembrino C , Consonni D, Pesenti A, Grasselli G.	Trials	2019	20	1	349	10.1186/s13063-019-3386-4	Articolo originale
98	Thrombotic thrombocytopenic purpura and defective apoptosis due to CASP8/10 mutations: the role of mycophenolate mofetil.	Fioredda F, Cappelli E, Mariani A, Beccaria A, Palmisani E, Grossi A, Ceccherini I, Venè R, Micalizzi C, Calvillo M, Pierri F, Mancini I , Peyvandi F , Corsolini F, Dufour C, Miano M.	Blood Advances	2019	3	21	3432	10.1182/bloodadvances.201900575	Articolo originale
99	Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia.	Peri AM, Rossio R , Tafuri F, Benzecry V, Grancini A, Reda G, Bandera A, Peyvandi F .	Annals of Hematology	2019	98	12	2847	10.1007/s00277-019-03837-1	Lettera con dati
100	A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.	Young G, Liesner R, Chang TY, Sidonio RF, Oldenburg J, Jiménez-Yuste V, Mahlangu JN, Kruse-Jarres R, Wang M, Uguen M, Doral MY, Wright LY, Schmitt C, Levy GG, Shima M, Mancuso ME .	Blood	2019	134	24	2127	10.1182/blood.2019001869	Articolo originale
101	New therapies for von Willebrand disease.	Mannucci PM	Blood Advances	2019	3	21	3481	10.1182/bloodadvances.201900368	Articolo originale
102	The risk of cesarean delivery after labor induction among women with prior pregnancy complications: a subgroup analysis of the AFFIRM study.	Skeith L, Le Gal G, de Vries JJP, Middeldorp S, Goddijn M, Kaaja R, Gris JC, Martinelli I , Schleußner E, Petroff D, Langlois N, Rodger MA; AFFIRM investigators .	BMC Pregnancy Childbirth	2019	19	1	455	10.1186/s12884-019-2615-x	Multicentrico NO Profit
103	Assessing spleen stiffness by point shear-wave elastography: Is it feasible and reproducible in patients with chronic liver disease? Is it useful to predict portal hypertension?	Fraquelli M, Conti CB, Giunta M, Gridavilla D, Tosetti G, Baccarin A, Casazza G, D'Ambrosio R, Nicolini A, Primignani M, Vecchi M, Lampertico P, La Mura V	GastroHep	2019	1	5	205	https://doi.org/10.1002/ygh.2.362	Articolo originale
104	Management of rare acquired bleeding disorders.	Menegatti M , Biguzzi E , Peyvandi F .	Hematology-American Society of Hematology Education Program	2019	2019	1	80	10.1182/hematology.2019000066	Review
105	New therapies for von Willebrand disease.	Mannucci PM	Hematology-American Society of Hematology Education Program	2019	2019	1	590	10.1182/hematology.2019000368	Review
106	Novel evidence for a greater burden of ambient air pollution on cardiovascular disease.	Mannucci PM , Harari S, Franchini M.	Haematologica	2019	104	12	2349	10.3324/haematol.2019.225086	Review